| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Stem Cell Engineering Company Raises $25 Million
Posted on 07/18/2007 04:07:58 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Novocell, a stem cell engineering company based in San Diego, has raised $25 million in a Series C round. Led by Johnson & Johnson (JNJ) Development Corporation — with participation from existing investors Sanderling Ventures, Asset Management Company and Pacific Horizon Venture — the financing will support the company’s three platform technologies, all of which are targeted at treating chronic cellular diseases.
Through human embryonic stem cell (hESC) engineering, Novocell seeks to generate an essentially unlimited supply of therapeutic cell types. The company has developed a process to efficiently convert hESC into insulin-producing pancreatic endocrine cells, a potentially effective treatment for diabetes. Novocell’s cell encapsulation technology provides a means by which such cells — by providing a protective, biocompatible coating that shields them from the immune system — could be delivered to patients without the need for chronic immunosuppression.
Phase I/II trials are currently underway, looking at the safety and efficacy of subcutaneous implants of encapsulated human primary islet allografts in patients with type 1 diabetes. These encapsulated islets release human insulin via natural mechanisms in response to the recipient’s blood glucose concentration.
Novocell also is using its technology to explore treatments for cancer. The company’s drug discovery efforts are focused on examining the key similarities between cancer stem cells and hESCs.
Novocell’s Series B financing was for $7 million and took place back in October 2001.
RELATED READING:
- There He Goes Again - The Stem Cell Dogma
- FDA Green Lights Harvest’s Stem Cell Trial
- US Stem Cell Policy: ceding the competitive edge
Med Tech Sentinel is a regular contributor to BioHealth Investor
_________________
Med Tech Sentinel
Novocell, a stem cell engineering company based in San Diego, has raised $25 million in a Series C round. Led by Johnson & Johnson (JNJ) Development Corporation — with participation from existing investors Sanderling Ventures, Asset Management Company and Pacific Horizon Venture — the financing will support the company’s three platform technologies, all of which are targeted at treating chronic cellular diseases.
Through human embryonic stem cell (hESC) engineering, Novocell seeks to generate an essentially unlimited supply of therapeutic cell types. The company has developed a process to efficiently convert hESC into insulin-producing pancreatic endocrine cells, a potentially effective treatment for diabetes. Novocell’s cell encapsulation technology provides a means by which such cells — by providing a protective, biocompatible coating that shields them from the immune system — could be delivered to patients without the need for chronic immunosuppression.
Phase I/II trials are currently underway, looking at the safety and efficacy of subcutaneous implants of encapsulated human primary islet allografts in patients with type 1 diabetes. These encapsulated islets release human insulin via natural mechanisms in response to the recipient’s blood glucose concentration.
Novocell also is using its technology to explore treatments for cancer. The company’s drug discovery efforts are focused on examining the key similarities between cancer stem cells and hESCs.
Novocell’s Series B financing was for $7 million and took place back in October 2001.
RELATED READING:
- There He Goes Again - The Stem Cell Dogma
- FDA Green Lights Harvest’s Stem Cell Trial
- US Stem Cell Policy: ceding the competitive edge
Med Tech Sentinel is a regular contributor to BioHealth Investor
_________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Newmark's Door
- The Family CEO
- Ludwig von Mises Institute
- Credit Bloggers
- Wishing Wealth
- Financial Skeptic
Examples
Boucher On The Big Picture - Thu Aug 14, 2008 04:54PM
Watch Interest Rates Next For Clue as to When Downside R [read more]
Watch Interest Rates Next For Clue as to When Downside R [read more]
Morpheus Trading - Thu Aug 14, 2008 07:54AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Editorial Spotlight - Fri Aug 15, 2008 10:33AM
They say the most dangerous enemy is the one you don’ [read more]
They say the most dangerous enemy is the one you don’ [read more]
<< My Home | TheMoneyBlogs Home